AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta ...

Since 2024, AbbVie has launched two medications [Emblaveo and Vyalev] that have received their first approval, while Sanofi has only one [Merilog]. AbbVie's R&D portfolio includes more than 90 ...

For instance, February 2025, AbbVie, announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as the first and only fixed-dose, intravenous, ...

PwC has released its latest Global Top 100 report ranking the largest public companies by market cap as of the end of March 2024.

The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, GSK announced. An antibiotic stewardship intervention at urgent care ...

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia ...